Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectinlike receptor NKG2D. To redirect NK cells against tumor cells we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the "knob into hole" heterodimerization strategy, in which "knob" and "hole" variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively.
Introduction
Natural Killer (NK) cells are cytotoxic cells, belonging to innate immunity, which play a major role in host response against different pathogens, such as viruses (Bukowski et al., 1985) , bacteria or parasites (Tay et al., 1998) . It is also now well established that NK cells are involved in cancer immunosurveillance (Kim et al., 2000; Smyth et al., 2002) . Despite no expression of antigen-specific receptors, such as T-or B-cell receptors (TcR and BcR), NK cells are able to recognize infected or malignant cells by several inhibitory or activating receptors, which act in balance either to induce NK cell tolerance towards normal cells or to promote NK cell activation and lysis of infected or tumor cells (Raulet and Vance, 2006) . While inhibitory receptors, such as the killer immunoglobulin-like inhibitory receptors (KIR), are able to recognize the classical major histocompatibility class I (MHC I) proteins, whose expression is often lost or downregulated on infected (Lodoen and Lanier, 2005) or malignant cells (Garrido et al., 1997) , activating receptors, such as the natural cytotoxicity receptors (NCR) NKp30, NKp44 and NKp46 or the natural killer group 2 D (NKG2D) receptor, are able to recognize different ligands over-expressed on transformed cells (Moretta et al., 2001 ).
The activating NKG2D receptor has been particularly studied, both in humans and in mice. It is homogeneously expressed on all human and mouse NK cells (Bauer et al., 1999; Jamieson et al., 2002) , but also on all human and mouse activated CD8+ T cells, where it acts as a TcR co-activator (Groh et al., 2001; Jamieson et al., 2002) . Several MHC class I Chain-related proteins A and B (MICA and MICB) (Bahram et al., 1994) and the retinoic acid early transcripts (RAET1E, G, H, I, L, N) (IMGT Repertoire (RPI); http://imgt.cines.fr) (Cosman et al., 2001; Jan Chalupny et al., 2003) . In mice, NKG2D ligands include the minor histocompatibility antigen H60 (Malarkannan et al., 1998) , the retinoic acid early transcript 1 molecules α, β, γ, δ and ε (Rae1α-ε) (Cerwenka et al., 2000) and the murine UL16-binding protein-like transcript 1 molecule (Mult1) (Carayannopoulos et al., 2002) . All these ligands are stress-induced proteins and have been identified on various tumor cell types, such as human epithelial carcinomas, melanomas, gliomas and leukemias (Pende et al., 2002; Vetter et al., 2002; Friese et al., 2003; Salih et al., 2003) or mouse epithelial carcinomas and lymphomas (Cerwenka et al., 2000; Diefenbach et al., 2000; Carayannopoulos et al., 2002) . However, during tumor progression, malignant cells lose frequently NKG2D ligand expression, as a consequence of tumor variant selection (Vetter et al., 2004; Carbone et al., 2005) , contact inhibition (Zou et al., 2006) or proteolytic shedding (Salih et al., 2002; Salih et al., 2003) , and thus escape to NK cell recognition.
Several studies have established that transfection of human tumor cells with genes encoding NKG2D ligands sensitizes these cells to NK cell-mediated lysis in vitro, in an NKG2D-dependent pathway (Friese et al., 2003; Busche et al., 2006) . It has also been demonstrated in vivo that transfected murine tumor cells expressing Rae1 or H60 are rejected by NK cells, while parental tumor cells critically grow, and that rejection is associated with T cell response priming (Diefenbach et al., 2001) .
To bypass the need of a gene therapy, we designed here bifunctional proteins able to bind tumor cells through specific antibody structures and to coat tumor cell surface with NKG2D ligands. These new bifunctional proteins were produced according to the "knob into hole" strategy, which allows the preferential heterodimerization of two heavy chains of distinct origin by changing two amino acids in their CH3 domains, and thus the production of recombinant bispecific antibodies (Ridgway et al., 1996; Merchant et al., 1998) . In the present study, we assembled through this strategy two different anti-tumor associated antigen (TAA) scFv with the mouse NKG2D ligand H60. After showing the specificity of these new bifunctional proteins for two targeted TAAs, we demonstrated their capacity to stimulate NKG2D-dependent tumor cell lysis by murine NK cells. 
Materials and methods

Tumor cell lines
Human acute monocytic leukemia THP-1 [expressing Fc receptors (FcR) FcγRI and FcγRII] and human breast carcinoma SK-BR-3 (expressing HER2) were obtained from the American Type Culture Collection (Rockville, MD) and maintained as described by the manufacturer. The murine colon carcinoma MC38 expressing CEA (C15.4.3.AP) cell line (kindly provided by Dr. J. Primus, Department of Pathology, Vanderbilt University Medical Center, Nashville, TN (Clarke et al., 1998) ), the murine melanoma B16 expressing HER2 cell line (kindly provided by Dr A. Donda, Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Switzerland (Stirnemann et al., 2008) and the murine T lymphoma RMA expressing CEA cell line, obtained by electro-transfection (250 V, 960 µF, 5 µg of DNA) of RMA cells with plasmid containing human CEA cDNA (Pelegrin et al., 1992) , were maintained in DMEM/F12 (1:1) supplemented with 2 mmol/L Lglutamine, 10% fetal calf serum (FCS), penicillin (100 units/ml)/streptomycin (100 µg/ml), and geneticin (0.5 mg/ml; Life Technologies, Grand Island, NY).
Vectors construction
The sequences of the different primers used for the construction of the bifunctional proteins are given in (Deyev et al., 2003) ) were amplified by PCR using primers P1/P2 and P3/P4. The amplified fragments were next digested and inserted in frame in plasmid ps878 (kindly provided by Dr P. Schneider, Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Switzerland (Schneider, 2000) ) encoding human IGHG1 Fc fragment (hinge, CH2 and CH3; GenBank/EMBL/IMGT/LIGM-DB accession No. X70421), with the signal sequence of the influenza virus hemagglutinin (HA) to allow protein secretion by mammalian cells. Knob variants of each construction were obtained by site-directed mutagenesis (PROMEGA Kit) in the IGHG1 CH3 sequence using primers P5/P6 (Xie et al., 2005) . this construction was obtained by site-directed mutagenesis using primers P7/P8 (Xie et al., 2005) . Site-directed mutagenesis efficiency was verified by sequencing.
Bifunctional proteins expression and purification
HEK 293 cells (ATCC CRL-1573) were grown in DMEM/F12 (1:1) supplemented with 2 mmol/L L-glutamine, 10% FCS and penicillin (100 units/ml)/streptomycin (100 µg/ml) and transfected with each mutant vector using FuGene 6 reagent (Roche Applied Science, Indianapolis, IN), as recommended by the manufacturer. Clones were selected by limit dilution with medium containing geneticin (0.8 mg/ml).
Culture supernatant of each clone was assayed for bifunctional proteins production by western blotting, as below. 
Murine Natural Killer cells preparation
Murine NK cells used as effectors in chromium release assays were prepared from a C57BL/6 spleen. Briefly, spleen was dilacerated, aggregates were eliminated on a 30 µm filter (Miltenyi Biotec, Auburn, CA), and splenic cells were cultured for 5 days in DMEM/F12 (1/1) supplemented with 2 mmol/L L-glutamine, 10% FCS, penicillin (100 units/ml)/streptomycin (100 µg/ml), non-essential amino acids, 1 µmol/L 11 inserm-00325786, version 1 -11 Sep 2009 sodium pyruvate (Life Technologies), 50 µmol/L β-mercaptoethanol, and recombinant human interleukin-2 (5000 units/ml) (Proleukin, Chiron, Emeryville, CA). After 5 days, adherent cells, corresponding to lymphokine activated killer (LAK) cells were recovered and used as effectors in chromium release assays.
Chromium-release assays
Natural Killer cell-mediated cytotoxicity was measured by the chromium release assay. Tumor target cells (2 x 10 5 in 100 µl) were co-incubated for 1 h at 37°C with, at the same time, 100 µCi of 51 Cr and 5 µg, or less if specified, of the studied bifunctional protein or antibody. After washing, the labeled tumor target cells were Recombinant H60-Fc protein was tested in a reverse antibody-dependent cellmediated cytotoxicity (ADCC) lysis assay for its capacity to induce NK-mediated tumor cell lysis. In a chromium release assay using NKG2D-expressing IL-2 activated murine NK cells (LAK cells) as effectors ( Figure 3B ), pre-incubation of the THP-1 cells, which are known to express FcRs, with rH60-Fc induced a specific increase of THP-1 cells lysis ( Figure 3C , black bars). This lysis was reduced to background level ( Figure 3C , white bars) when THP-1 cells were pre-incubated with an FcR blocking reagent ( Figure 3C , hatched bars), confirming that this lysis was exclusively triggered by the coating of these cells with H60.
TAA binding capacity of the bifunctional proteins
Binding capacity of the two purifed bifunctional proteins to tumor cells expressing Figure 5D , black bars). Finally, specific lysis induced by the two bifunctional proteins studied was abrogated by pre-incubation of murine NK cells with an anti-mouse NKG2D antibody ( Figure 5B and D, hatched bars) . This clearly demonstrated that the increase in NK cell-mediated lysis was only the result of H60 engagement, brought exogenously thanks to these two bifunctional proteins, by the activating receptor NKG2D present on NK cells. Moreover, stimulation of NKG2D by our anti-HER2 (scFv 4D5/rH60)-Fc bifunctional protein seems to be more efficient than activation of Fc receptors by anti-HER2 trastuzumab antibody to induce NKmediated SK-BR-3 tumor cell lysis, whatever the dose tested ( Figure 5C ).
Discussion
It has been previously described the in vivo rejection of several types of tumor cells when these ones are genetically manipulated to express at the cell surface ligands of NKG2D, an activating receptor expressed on NK and T cells Diefenbach et al., 2001; Friese et al., 2003; Oppenheim et al., 2005; Busche et al., 2006) . an efficient and specific NK-mediated lysis of these cells, in an NKG2D-dependent pathway.
Bispecific antibodies and bifunctional molecules have been largely exploited in cancer immunotherapy (Koelemij et al., 1999; Peipp and Valerius, 2002; Kontermann, 2005) , notably in order to favour the recruitment and/or the activation of effector cells to the tumoral site, by immuno-targeted cytokines (Gillies et al., 1991; Hoogenboom et al., 1991) or agonist antibodies against activating receptors expressed on cytotoxic cells (Van Dijk et al., 1989) , thanks to antibody structures specific for TAAs. Many strategies have been developed to this aim, such as hybrid hybridomas (quadromas (Milstein and Cuello, 1983) ) or chemical conjugation (Karpovsky et al., 1984; Robert et al., 1996) . Nevertheless, production of this type of molecules is frequently limited in terms of quality and/or quantity, two major criteria for their use in humans as therapeutic agents. While quadroma method leads to the formation of many different contaminant forms (up to nine (Carter, 2001) ) via uncertain rearrangement of the two heavy chains and the two light chains in presence, chemical conjugation, using for example Fab' fragments of monoclonal antibodies (Robert et al., 1999) , is often associated with poor production outputs. Genetic engineering allowed the development of other formats such as diabody (Arndt et al., 1999) , single-chain bispecific antibody (Loffler et al., 2000) , or single-chain diabody, but unfortunately frequently associated with short half-lives in vivo (Kontermann, 2005) . To bypass this last point, however, an original study recently proposed the fusion of these small molecules with human serum albumin, strongly improving their pharmacokinetic properties (Muller et al., 2007) .
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In a previous study (Germain et al., 2005) , we demonstrated the ability of chemical conjugates associating recombinant MICA molecules with Fab' fragments of different monoclonal anti-tumor antibodies to specifically bind TAAs and to stimulate NKG2D-dependent lysis of resistant tumor cells by human NK cells. In the same way, an antitumor activity against human myeloma has been described with a recombinant ULBP2-scFv anti CD138 molecule (von Strandmann et al., 2006) . Here, in the perspective to produce higher amounts of in vivo usable bifunctional proteins we chose to use the "knob into hole" strategy, which was developed to produce bispecific antibodies easily purified from culture supernatant (Ridgway et al., 1996; Merchant et al., 1998) , based on the preferential heterodimerization of two distinct heavy chains of human immunoglobulin. Recently, Xie et al. applied similarly this technology for the production of a bispecific antibody associating an anti-HER2 scFv to an anti-CD16 scFv to stimulate in vitro CD16-dependent tumor cell lysis by PBMC (Xie et al., 2005) . In contrast to this report, the (scFv anti-TAA)/rH60-Fc bifunctional proteins produced here associate an anti-tumor scFv to a recombinant form of one of the natural ligands of the mouse NKG2D receptor, H60, able as shown for MICA in humans to induce mouse NK cells cytotoxicity when expressed on tumor cells (Cerwenka et al., 2000; Diefenbach et al., 2000) . We postulated that the intermediate affinity of H60 for mouse NKG2D, compared with other mouse NKG2D ligands (O'Callaghan et al., 2001; Carayannopoulos et al., 2002) conjugates to activate T-lymphocytes, in soluble form or coated on tumor cells (Robert et al., 2001) . Using Ca2+ mobilization assays, we demonstrated that these conjugates, associating monomeric HLA-A2/Flu complexes to anti-TAA Fab' fragments, can efficiently activate CTL only when oligomerized on the surface of tumor cells.
In the present study, we demonstrated that the two produced (scFv anti-TAA)/rH60- 
